Thymoquinone: shield and sword against SARS-CoV-2
Open Access
- 20 May 2020
- journal article
- research article
- Published by Andover House Inc in Precision Nanomedicine
- p. 541-548
Abstract
Since its emergence, the epidemic scale of the new coronavirus (SARS-CoV-2) has increased at an extraordinary rate. Governments, medical personnel, researchers and companies work at the limit of their capabilities, in attempts to combat the virus. Companies are giving up current projects and change their activities to help fighting the virus. In this difficult time, every piece of useful information is valuable. Here, we bring to the attention of the scientific and medical community thymoquinone (TQ), a substance unknown to experts in western countries, which holds the promise to help treating people infected with this novel virus: (1) by inhibiting its proliferation, (2) by killing it, (3) by killing the bacteria associated with pneumonia, (4) by its anti-inflammatory and (5) immunomodulatory effect – perhaps acting synergistically, or even as a prophylactic remedy to prevent SARS-CoV-2 infection. However, due to the volatility of TQ, bioavailability in infected organs, specifically the lungs, is low. This is where nanomedicine is challenged. Nanocarriers targeting the lungs exist and TQ has already been successfully used in nanomedicines targeting different organs, except the lungs. Thus, there is not a long way to go. It was an anecdotal case report that stimulated the investigation of the therapeutic effect of TQ and the derivation of a mechanism for its dual antiviral action, applicable to Covid-19. Furthermore, by exploiting the material published on the antiviral effect of TQ, we compared the antiviral mechanism of TQ with that of chloroquine (CQ) and hydroxychloroquine (HCQ). Our analysis indicates that the antiviral action of TQ is similar and most likely superior to that of CQ and HCQ, however, apparently without the adverse effects reported for CQ and HCQ. The broad antiviral spectrum and the mechanism by which TQ presumably neutralizes the new virus, justifies the hypothesis that TQ is effective to treat Covid-19. [READ ARTICLE](https://precisionnanomedicine.com/article/12984)Keywords
This publication has 35 references indexed in Scilit:
- Comparative immune response and pathogenicity of the H9N2 avian influenza virus after administration of Immulant®, based on Echinacea and Nigella sativa, in stressed chickensComparative Immunology, Microbiology and Infectious Diseases, 2019
- Targeting of Thymoquinone-loaded mesoporous silica nanoparticles to different brain areas: In vivo studyLife Sciences, 2019
- Nigella sativa essential oil and its bioactive compounds as resistance modifiers against Staphylococcus aureusPhytotherapy Research, 2019
- Natural therapeutic approach of Nigella sativa (Black seed) fixed oil in management of SinusitisIntegrative Medicine Research, 2018
- Preclinical and clinical effects of Nigella sativa and its constituent, thymoquinone: A reviewJournal of Ethnopharmacology, 2016
- The effects of Nigella sativa (Ns), Anthemis hyalina (Ah) and Citrus sinensis (Cs) extracts on the replication of coronavirus and the expression of TRP genes familyMolecular Biology Reports, 2014
- Immunomodulatory and therapeutic properties of the Nigella sativa L. seedInternational Immunopharmacology, 2005
- Effects of chloroquine on viral infections: an old drug against today's diseasesThe Lancet Infectious Diseases, 2003
- Protective effect of black seed oil from Nigella sativa against murine cytomegalovirus infectionInternational Journal of Immunopharmacology, 2000
- Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudineClinical Therapeutics, 1996